Validating the Spanish "Attitudes Toward Genomics and Precision Medicine" (AGPM).

Last updated: February 3, 2025
Sponsor: Boston College
Overall Status: Active - Not Recruiting

Phase

N/A

Condition

N/A

Treatment

Attitudes Toward Genomics and Precision Medicine (Spanish)

Attitudes Toward Genomics and Precision Medicine (English)

Clinical Study ID

NCT06386861
24.210.01e
  • Ages > 18
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

The investigators aim to evaluate English and Spanish versions of the "Attitudes toward genomics and precision medicine" instrument (AGPM). This study will help validating a Spanish version of the AGPM among people identifying as Hispanic, Latino, or Latina. Having a valid instrument is important for developing tailored interventions to decrease disparities in genomic healthcare for this population.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • adult (18+ yrs.)

  • identifying as Hispanic, Latino, or Latina

  • able to provide opt-in electronic informed consent

Exclusion

Exclusion Criteria:

  • under age 18 yrs.

  • not identifying as Hispanic, Latino, or Latina

  • not able to provide opt-in electronic informed consent

Study Design

Total Participants: 851
Treatment Group(s): 2
Primary Treatment: Attitudes Toward Genomics and Precision Medicine (Spanish)
Phase:
Study Start date:
April 14, 2024
Estimated Completion Date:
December 31, 2025

Study Description

The investigators will recruit 1,000 individuals (500 English-speaking and 500 Spanish-speaking) to complete the AGPM and previously validated instruments assessing health literacy and numeracy. Results will establish the psychometric properties of the Spanish version of the AGPM.

Connect with a study center

  • Boston College

    Chestnut Hill, Massachusetts 02467
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.